This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy and safety of donepezil in patients with Alzheimer’s disease in assisted living facilities


Rosenblatt, Adam, Gao, Jeff, Mackell, Joan, Richardson, Sharon


American Journal Of Alzheimer's Disease And Other Dementias, Volume: 25, No.: 6, Pages.: 483-489

Year of Publication



The aim of this 12-week, open-label study was to determine the safety and efficacy of donepezil in participants with Alzheimer’s disease (AD) residing in assisted living facilities (ALFs). Participants received 5 mg donepezil daily for 6 weeks followed by 10 mg daily for 6 weeks. Primary and secondary outcomes were change from baseline in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory 8 (NPI-8) scores, respectively. Safety was assessed by adverse events (AEs) and laboratory tests. Of the 97 participants, 76 completed the study. Mean MMSE score (18.7 at baseline) improved 1.8 points (P < .0001) at study end. Total NPI-8 score improved 1.8 points (P = .043). The most frequent AEs were nausea and diarrhea. Donepezil improved cognition and behavior and was safe and well tolerated. The results suggest a need for proactive screening and diagnosis of AD and support the value of treatment and use of donepezil in participants residing in ALFs.;

Bibtex Citation

@article{Rosenblatt_2010, doi = {10.1177/1533317510372923}, url = {}, year = 2010, month = {jun}, publisher = {{SAGE} Publications}, volume = {25}, number = {6}, pages = {483--489}, author = {A. Rosenblatt and J. Gao and J. Mackell and S. Richardson}, title = {Efficacy and Safety of Donepezil in Patients With Alzheimer{textquotesingle}s Disease in Assisted Living Facilities}, journal = {American Journal of Alzheimer{textquotesingle}s Disease and Other Dementias} }


administration & dosage, adverse, adverse effects, aged, aged, 80 and over, alzheimer disease, assisted living facilities, cognition, donezepil, drug effects, drug therapy, events, female, humans, indans, male, middle aged, neuropsychological tests, nootropic agents, piperidines, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes

Behaviour, Cognition, Other


Long Term Residential Care without medically trained staff

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime